Oral Ganciclovir in the Prevention of Cytomegalovirus Infection in Postkidney Transplant “CMV at Risk” Recipients: A Controlled, Comparative Study of Two Regimens (750 mg Bid and 500 mg Bid)
- 1 June 1998
- journal article
- clinical trial
- Published by Elsevier in Transplantation Proceedings
- Vol. 30 (4) , 1383-1385
- https://doi.org/10.1016/s0041-1345(98)00283-8
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- GanciclovirNew England Journal of Medicine, 1996
- Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDSNew England Journal of Medicine, 1996
- Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDSNew England Journal of Medicine, 1995
- Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus— and cytomegalovirus-seropositive patientsClinical Therapeutics, 1995
- A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal AllograftsNew England Journal of Medicine, 1989
- Cytomegalovirus infection and renal transplantationJournal of Antimicrobial Chemotherapy, 1989
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987
- INCIDENCE OF CYTOMEGALOVIRUS DISEASE IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS BASED ON DONOR/RECIPIENT PRETRANSPLANT IMMUNITYTransplantation, 1987
- EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATIONTransplantation, 1985
- Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replicationAntimicrobial Agents and Chemotherapy, 1984